1-4 of 4
Niall Curley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Piyanuch Kongtim, Mary-Elizabeth M. Percival, Timothy J Martins, Guangrong Qin, Niall Curley, Kelda M. Gardner, Sylvia Chien, Jin Dai, Vivian G. Oehler, C. Anthony Blau, Paul C. Hendrie, Ryan D. Cassaday, Anna B. Halpern, Bart L. Scott, Roland B. Walter, Heather Smith, Guido Marcucci, Pamela S. Becker
Journal: Blood
Blood (2022) 140 (Supplement 1): 1200–1202.
https://doi.org/10.1182/blood-2022-165801
Published: 2022
Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Pamela S. Becker, MD PhD, Vivian G. Oehler, MD, Carl Anthony Blau, MD, Timothy S Martins, PhD, Niall Curley, Sylvia Chien, Jin Dai, PhD, Nicole Kauer, Ka Yee Yeung, PhD, Ling-Hong Hung, PhD, Cody Hammer, Paul C. Hendrie, MD PhD, Mary-Elizabeth M. Percival, MD, Ryan D. Cassaday, MD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Kelda Gardner, PA-C, Mary Gwin, Heather Smith, PA-C, Andrew Carson, PhD, Bradley Patay, MD, Elihu H. Estey, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1269.
https://doi.org/10.1182/blood-2019-130996
Published: 2019
Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1885.
https://doi.org/10.1182/blood-2019-125383
Published: 2019
Journal Articles

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Kelda M Gardner, PA-C, Kathleen Shannon Dorcy, PhD RN, Rachele O'Leary, Donelle Rizzuto, RN, Roland B. Walter, MD PhD MS, Carole Shaw, Sunny So, RN, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Mary Beth M. Percival, MD, Anna B. Halpern, MD, Ryan D. Cassaday, MD, Janis L. Abkowitz, MD, Bethany Murphy, Niall Curley, Cody Hammer, Heather Smith, PA-C, Gabrielle A Zecha, PA-C, Frederick R. Appelbaum, MD, Soheil Meshinchi, MD PhD, Colleen Delaney, MDMSc, Todd M Cooper, DO, Katherine Tarlock, MD, Elihu H. Estey, MD, Pamela S. Becker, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2710.
https://doi.org/10.1182/blood-2018-99-116908
Published: 2018